Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DSG2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DSG2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DSG2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DSG2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DSG2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DSG2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DSG2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DSG2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003297012 | Liver | Cirrhotic | regulation of actin filament-based process | 152/4634 | 397/18723 | 1.12e-09 | 5.00e-08 | 152 |
GO:00341097 | Liver | Cirrhotic | homotypic cell-cell adhesion | 39/4634 | 90/18723 | 8.57e-05 | 9.25e-04 | 39 |
GO:00989016 | Liver | Cirrhotic | regulation of cardiac muscle cell action potential | 15/4634 | 27/18723 | 5.96e-04 | 4.63e-03 | 15 |
GO:004521612 | Liver | Cirrhotic | cell-cell junction organization | 70/4634 | 200/18723 | 7.23e-04 | 5.36e-03 | 70 |
GO:00989115 | Liver | Cirrhotic | regulation of ventricular cardiac muscle cell action potential | 8/4634 | 12/18723 | 2.59e-03 | 1.53e-02 | 8 |
GO:00029346 | Liver | Cirrhotic | desmosome organization | 7/4634 | 10/18723 | 3.29e-03 | 1.83e-02 | 7 |
GO:00341132 | Liver | Cirrhotic | heterotypic cell-cell adhesion | 25/4634 | 61/18723 | 3.80e-03 | 2.08e-02 | 25 |
GO:00860047 | Liver | Cirrhotic | regulation of cardiac muscle cell contraction | 15/4634 | 34/18723 | 1.05e-02 | 4.66e-02 | 15 |
GO:003297022 | Liver | HCC | regulation of actin filament-based process | 222/7958 | 397/18723 | 3.81e-08 | 8.30e-07 | 222 |
GO:003410912 | Liver | HCC | homotypic cell-cell adhesion | 55/7958 | 90/18723 | 2.81e-04 | 2.02e-03 | 55 |
GO:004521622 | Liver | HCC | cell-cell junction organization | 107/7958 | 200/18723 | 1.06e-03 | 6.11e-03 | 107 |
GO:009891111 | Liver | HCC | regulation of ventricular cardiac muscle cell action potential | 10/7958 | 12/18723 | 4.79e-03 | 2.02e-02 | 10 |
GO:009890111 | Liver | HCC | regulation of cardiac muscle cell action potential | 18/7958 | 27/18723 | 9.75e-03 | 3.66e-02 | 18 |
GO:003297020 | Oral cavity | OSCC | regulation of actin filament-based process | 209/7305 | 397/18723 | 1.89e-08 | 3.72e-07 | 209 |
GO:003410919 | Oral cavity | OSCC | homotypic cell-cell adhesion | 55/7305 | 90/18723 | 1.78e-05 | 1.73e-04 | 55 |
GO:00029348 | Oral cavity | OSCC | desmosome organization | 9/7305 | 10/18723 | 1.36e-03 | 6.62e-03 | 9 |
GO:00605378 | Oral cavity | OSCC | muscle tissue development | 185/7305 | 403/18723 | 2.60e-03 | 1.14e-02 | 185 |
GO:004521618 | Oral cavity | OSCC | cell-cell junction organization | 97/7305 | 200/18723 | 3.83e-03 | 1.57e-02 | 97 |
GO:00147067 | Oral cavity | OSCC | striated muscle tissue development | 174/7305 | 384/18723 | 6.45e-03 | 2.40e-02 | 174 |
GO:009890115 | Oral cavity | OSCC | regulation of cardiac muscle cell action potential | 17/7305 | 27/18723 | 1.01e-02 | 3.49e-02 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DSG2 | SNV | Missense_Mutation | novel | c.2128N>C | p.Glu710Gln | p.E710Q | Q14126 | protein_coding | tolerated(0.44) | benign(0.153) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
DSG2 | SNV | Missense_Mutation | rs748445394 | c.219N>G | p.Ile73Met | p.I73M | Q14126 | protein_coding | deleterious(0.01) | benign(0.254) | TCGA-EW-A1OY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
DSG2 | insertion | In_Frame_Ins | novel | c.2963_2964insATT | p.Thr988_Glu989insPhe | p.T988_E989insF | Q14126 | protein_coding | | | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
DSG2 | insertion | Frame_Shift_Ins | novel | c.759_760insGCCTGGGCAACAGAGCAAGACTCCATATCCAAAAAAAAGAAAAG | p.Lys254AlafsTer33 | p.K254Afs*33 | Q14126 | protein_coding | | | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
DSG2 | insertion | Frame_Shift_Ins | novel | c.617_618insCAAGAAATATATTAAATTTTTTTGTTTGT | p.Tyr207LysfsTer17 | p.Y207Kfs*17 | Q14126 | protein_coding | | | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DSG2 | deletion | Frame_Shift_Del | novel | c.654delN | p.Glu219ArgfsTer19 | p.E219Rfs*19 | Q14126 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
DSG2 | SNV | Missense_Mutation | rs751064437 | c.2915N>T | p.Ser972Phe | p.S972F | Q14126 | protein_coding | deleterious(0.01) | possibly_damaging(0.87) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
DSG2 | SNV | Missense_Mutation | | c.1045G>C | p.Asp349His | p.D349H | Q14126 | protein_coding | deleterious(0.01) | possibly_damaging(0.897) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DSG2 | SNV | Missense_Mutation | novel | c.2635G>C | p.Glu879Gln | p.E879Q | Q14126 | protein_coding | tolerated(0.09) | possibly_damaging(0.454) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DSG2 | SNV | Missense_Mutation | novel | c.134N>C | p.Val45Ala | p.V45A | Q14126 | protein_coding | deleterious(0.02) | benign(0.006) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |